Building a commercial team and customer workflow that provides access to our new capacity within our plasmid and mRNA CDMO business.

Boutique firm boasting a valuable network of life sciences sales and executive professionals and consultants with strategic access to science hubs in North America, Europe, and Asia, and commercial launch experiences developing client strategies to bring new technologies to market.

Hired to oversee buildout of commercial organization to maximize/accelerate business growth opportunities that create customer/shareholder value following recent expansion phase of CDMO’s viral vector process development and cGMP production facility. Member of acquisition team evaluating/executing on inorganic growth opportunities. Reporting to CEO and Board of Directors leading team of 40.

Part of leadership steering expansive growth through IPO. Hired to build GMP business unit infrastructure and blend into core business operations to prepare for growth. Increased productivity 20% by restructuring client services. Reported to division chief, leading team of 40. Trilink is a global leader in synthesis of custom RNA (and mRNA transcripts), DNA, and NTPs. Founded in 1996, company played a role in COVID vaccine production. Part of Maravai LifeSciences Holdings, received IPO in 2020 valued at $1.6B.

VERTE SANTE VENTURE PARTNERS (VSVP) is an investor, strategic advisor team of highly skilled C-suite executives who accelerate value creation for emerging growth businesses within the $4.5T global wellness segment.

Delivered product revenue over plan from 2014 to 2015 by developing high-value key accounts, driving revenue growth to 75%. Introduced strategy for building B2B offering, resulting in multiple contracts within POC molecular diagnostic, NGS laboratories, and pharmaceutical companies.Biomatrica is a biotechnology company that develops chemicals for ambient temperature preservation of biological materials for purpose of expanding the availability and accuracy of medical diagnostics and research.

Formed and managed US P&L for 2011 to 96% of revenue and 85% of expense budget. Drove revenue to 50% growth vs. prior year through Q3 of 2013.Singulex is the developer and leading provider of single molecule counting (SMCTM) technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultra-sensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.

Expanded sales team more than 30% globally, establishing offices in India, Korea, and China, enabling direct sales. Realized 40%+ revenue growth within North America vs. prior year.Protein Simple develops and commercializes proprietary systems and consumables for protein analysis that help reveal new insight into the nature of proteins. Founded in 2001; acquired by Bio-Techne in 2004 for $300M.

Converted US sales structure to an expandable direct team in two years with growth rate of 2.5x industry, driving revenue from $9M to $18M. Rebuilt company into an attractive acquisition target by increasing margins and revenue to maintain positive EBITA (over several quarters). Sold to ProteinSimple in 2009.Alpha Innotech develops, manufactures, and markets digital imaging and detection systems for life science research and drug discovery market

Developed sales and expense budgets for UK, Ireland, Germany, France, Belgium, and Netherlands. Increased core business from $7M to $19M (2004–2006). Finished 2005 at 95% of sales plan and 28% growth vs. 2004. Molecular Devices supplies analytical systems, including instruments, software, and reagents to accelerate and improve drug discovery and basic life science research. Founded in 1983; acquired by MDS Inc. in 2007 for $615M.

Direct Sales for Life Science prodcuts in San Diego and Nevada.

Responsible for Direct Sales. Top performer in North America in 2002; President’s Club award in 2003.Bio-Rad is a global leader in developing, manufacturing, and marketing broad range of innovative products for life science research and clinical diagnostic markets to advance discovery process and improve health care. Publicly traded; 2021 revenue at $2.92B and 7,900 employees.